29 November 2022
In Conversation With… Our Advanced Therapies Week 2023 Speakers
Our Phacilitate team has been busy catching up with experts across the cell and gene therapy field: our confirmed speakers for Advanced Therapies Week 2023. With an agenda covering the biggest topics in ATMP right now, from the workforce bottleneck to the newest technological advances, our speakers give an insight into what to expect from their individual sessions and share what they are most excited for as the community prepares to reconvene in Miami in January.
Latest Content
Don’t Miss Out on Our Latest Webinar
Up Next: Setting the Stage for Successful Clinical Manufacturing of Cell and Gene Therapies
Are you preparing to advance your therapy into the clinic? Join us as a panel of industry experts shed light on where most early-stage biotechs go wrong in overestimating their readiness. Encouraging you to take an in-depth look at your product, capabilities, technologies, processes, and team, this panel discussion will prepare you for success as you bring your product from the bench to patients worldwide.
08:00 PDT | 11:00 EDT | 16:00 GMT
Zoom
Access Our Webinar Library
Latest Podcast Episodes
People and ideas that inspire the advanced therapies industry
Our eBooks & Infographics
In this infographic, we have detailed some key considerations when choosing your plasmids for CAR-T development.
As we celebrate 10 years of CAR-T, the Phacilitate team is delighted to present this eBook, in partnership with WuXi Advanced Therapies, as a comprehensive resource for CAR-T development.
Gaining market and patient access in Europe has presented many cell and gene therapy companies with barriers. The advanced therapies industry is currently facing a dilemma: scientific advancement is exceeding market and reimbursement adaptation.
Advanced therapies’ market access is a hot topic. Joining Phacilitate to shed some light on market access struggles are Director at NJ Redfern Limited and ex-bluebird bio UK GM Nicola Redfern, former SVP & CBO at Novartis Gene Therapies and current AviadoBio CEO Lisa Deschamps, and, Vice President and Global Head of Value and Access, at Novartis, Tay Salimullah.
What’s preventing developers from designing mechanistically relevant assays? This report examines this question, focusing on the identification and measurement of appropriate CQAs, the value of fit-for-purpose analytics technologies and what the future of CGT manufacturing analytics should look like.
May 2022 marks the month 17-year-old Emily Whitehead, the first pediatric patient in the world to receive CAR-T cell therapy, celebrates a momentous milestone: 10 years’ cancer free. All month Phacilitate will be joining to celebrate 10 years of CAR-T!
Welcome to Phacilitate’s first Women in Advanced Therapies eBook, commemorating International Women’s Day 2022.
A snapshot of the industry’s approach to commercialisation, presented as a handy infographic.
A collection of the outcomes from the roundtables and panels that took place at Advanced Therapies Connect 2020
This e-book examines 15 of the world’s leading immuno-oncology biotechnology companies, providing you with an at-a-glance view plus more detailed information on how their pipelines are developing.
